Leading tissue engineering researchers at Wake Forest Intstitute for Regenerative Medicine have published a new study in the journal Annals of Biomedical Engineering demonstarting the ability of Synthecon's RCCS to create liver-tumor hybrid organoids. This study was able to show that organoids formed within the RCCS can recapitulate host tissue to better understand colon carcinoma progression, drug suceptibility and resistance.
See the original study : Liver-Tumor Hybrid Organoids for Modeling Tumor Growth and Drug Response In Vitro